{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:12:50Z","timestamp":1787065970298,"version":"build-2736575974"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["ERC-2023-STG101117469"],"award-info":[{"award-number":["ERC-2023-STG101117469"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","interventional.theclinics.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Interventional Cardiology Clinics"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.iccl.2024.06.006","type":"journal-article","created":{"date-parts":[[2024,8,9]],"date-time":"2024-08-09T23:39:09Z","timestamp":1723246749000},"page":"517-525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antithrombotic Therapy in Patients with Complex Percutaneous Coronary Intervention and Cardiogenic Shock"],"prefix":"10.1016","volume":"13","author":[{"given":"Jose Ignacio","family":"Larrubia Valle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crist\u00f3bal A.","family":"Urbano-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.iccl.2024.06.006_bib1","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s40265-017-0806-1","article-title":"Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies","volume":"77","author":"Costa","year":"2017","journal-title":"Drugs"},{"issue":"20","key":"10.1016\/j.iccl.2024.06.006_bib2","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/eurheartj\/ehv053","article-title":"Duration of dual antiplatelet therapy after drug-eluting stent implantation: will we ever reach a consensus?","volume":"36","author":"Valgimigli","year":"2015","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.006_bib3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4244\/EIJ-D-20-00885","article-title":"Antithrombotic therapy after percutaneous coronary intervention of bifurcation lesions","volume":"17","author":"Zimarino","year":"2021","journal-title":"EuroIntervention"},{"key":"10.1016\/j.iccl.2024.06.006_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ijcard.2016.03.033","volume":"212","author":"Crimi","year":"2016","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.006_bib5","doi-asserted-by":"crossref","first-page":"e1222","DOI":"10.4244\/EIJY15M08_04","article-title":"Left main or proximal left anterior descending coronary artery disease location identifies high-risk patients deriving potentially greater benefit from prolonged dual antiplatelet therapy duration","volume":"11","author":"Costa","year":"2016","journal-title":"EuroIntervention"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.006_bib6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.4244\/EIJV5I1A9","article-title":"Assessment of the SYNTAX score in the Syntax study","volume":"5","author":"Serruys","year":"2009","journal-title":"EuroIntervention"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.006_bib7","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2016.07.760","article-title":"Efficacy and safety of dual antiplatelet therapy after complex PCI","volume":"68","author":"Giustino","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.006_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jcin.2021.09.039","article-title":"Defining percutaneous coronary intervention complexity and risk: An analysis of the United Kingdom BCIS database 2006-2016 [published correction appears in JACC Cardiovasc Interv. 2022 Aug 22;15(16):1694-1695]","volume":"15","author":"Protty","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.006_bib9","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jcin.2019.01.212","article-title":"Characterization of the Individual Patient Risk After Percutaneous Coronary Intervention: At the Crossroads of Bleeding and Thrombosis","volume":"12","author":"Giustino","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.006_bib10","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1507854","article-title":"Bivalirudin or unfractionated heparin in acute coronary syndromes","volume":"373","author":"Valgimigli","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"9698","key":"10.1016\/j.iccl.2024.06.006_bib11","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(09)61484-7","article-title":"Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial","volume":"374","author":"Mehran","year":"2009","journal-title":"Lancet"},{"issue":"10366","key":"10.1016\/j.iccl.2024.06.006_bib12","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/S0140-6736(22)01999-7","article-title":"Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: A randomised trial","volume":"400","author":"Li","year":"2022","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.iccl.2024.06.006_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1161\/CIRCULATIONAHA.123.063946","article-title":"Bivalirudin versus heparin during PCI in NSTEMI: Individual patient data meta-analysis of large randomized trials","volume":"148","author":"Bikdeli","year":"2023","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.006_bib14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/MCA.0b013e32832cff08","article-title":"Safety and efficacy of a prolonged bivalirudin infusion after urgent and complex percutaneous coronary interventions: A descriptive study","volume":"20","author":"Cortese","year":"2009","journal-title":"Coron Artery Dis"},{"issue":"5","key":"10.1016\/j.iccl.2024.06.006_bib15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: Primary results of the FABOLUS-FASTER trial [published correction appears in Circulation. 2020 Aug 4;142(5):e71]","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation"},{"issue":"38","key":"10.1016\/j.iccl.2024.06.006_bib16","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145]","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib17","first-page":"e4","volume":"145","author":"Lawton","year":"2022","journal-title":"Circulation"},{"issue":"9909","key":"10.1016\/j.iccl.2024.06.006_bib18","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: A pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"issue":"41","key":"10.1016\/j.iccl.2024.06.006_bib19","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1093\/eurheartj\/ehy562","volume":"39","author":"Stone","year":"2018","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.iccl.2024.06.006_bib20","first-page":"1266","article-title":"Pharmacodynamic effects of cangrelor in elective complex PCI: Insights from the POMPEII Registry","volume":"18","author":"Gargiulo","year":"2023","journal-title":"EuroIntervention"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib21","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib22","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/eurheartj\/ehx503","article-title":"Case-based implementation of the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease","volume":"39","author":"Collet","year":"2018","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.iccl.2024.06.006_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/eurheartj\/ehy394","article-title":"2018 ESC\/EACTS guidelines on myocardial revascularization","volume":"40","author":"Neumann","year":"2019","journal-title":"Eur Heart J"},{"issue":"S1","key":"10.1016\/j.iccl.2024.06.006_bib24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1002\/ccd.30077","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention","volume":"99","author":"Li","year":"2022","journal-title":"Catheter Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib25","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.jcin.2023.12.011","article-title":"Ticagrelor vs clopidogrel for complex percutaneous coronary intervention in chronic coronary syndrome","volume":"17","author":"Lattuca","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.006_bib26","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/ehjacc\/zuab077","article-title":"Twelve-month clinical outcomes in patients with acute coronary syndrome undergoing complex percutaneous coronary intervention: insights from the ISAR-REACT 5 trial","volume":"10","author":"Coughlan","year":"2021","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.006_bib27","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting","volume":"73","author":"Costa","year":"2019","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.iccl.2024.06.006_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1093\/ehjcvp\/pvad063","article-title":"External validity of the PRECISE-DAPT score in patients undergoing PCI: a systematic review and meta-analysis","volume":"9","author":"Munaf\u00f2","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.iccl.2024.06.006_bib29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ahj.2020.01.014","article-title":"A\u00a04-item PRECISE-DAPT score for dual antiplatelet therapy duration decision-making","volume":"223","author":"Costa","year":"2020","journal-title":"Am Heart J"},{"issue":"18","key":"10.1016\/j.iccl.2024.06.006_bib30","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.jacc.2017.09.011","article-title":"Lesion complexity and outcomes of extended dual antiplatelet therapy after percutaneous coronary intervention","volume":"70","author":"Yeh","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2024.06.006_bib31","doi-asserted-by":"crossref","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: Individual patient level meta-analysis of randomised controlled trials [published correction appears in BMJ. 2022 Jan 27;376:o239]","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"19","key":"10.1016\/j.iccl.2024.06.006_bib32","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.jacc.2020.03.011","article-title":"Ticagrelor with or without aspirin after complex PCI","volume":"75","author":"Dangas","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.iccl.2024.06.006_bib33","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.carrev.2023.11.002","article-title":"Short duration of dual antiplatelet therapy following complex percutaneous coronary intervention: A systematic review and meta-analysis","volume":"61","author":"Eid","year":"2024","journal-title":"Cardiovasc Revasc Med"},{"key":"10.1016\/j.iccl.2024.06.006_bib34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ahj.2022.10.006","article-title":"P2Y12 inhibitors monotherapy in patients undergoing complex vs non-complex percutaneous coronary intervention: A meta-analysis of randomized trials","volume":"255","author":"Oliva","year":"2023","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib35","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ehjcvp\/pvac071","article-title":"Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: A collaborative systematic review and meta-analysis","volume":"9","author":"Nicolas","year":"2023","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"1","key":"10.1016\/j.iccl.2024.06.006_bib36","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-39213-3","article-title":"P2Y12 inhibitor monotherapy after complex percutaneous coronary intervention: A systematic review and meta-analysis of randomized clinical trials","volume":"13","author":"Sotomi","year":"2023","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.006_bib37","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after complex percutaneous coronary interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"33","key":"10.1016\/j.iccl.2024.06.006_bib38","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1093\/eurheartj\/ehac284","article-title":"Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: A MASTER DAPT trial sub-analysis","volume":"43","author":"Valgimigli","year":"2022","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.iccl.2024.06.006_bib39","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: A meta-analysis of randomized trials","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.006_bib40","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.jcin.2024.03.017","article-title":"An aspirin-free strategy for immediate treatment following complex percutaneous coronary intervention","volume":"17","author":"Yamamoto","year":"2024","journal-title":"JACC Cardiovasc Interv"},{"issue":"3","key":"10.1016\/j.iccl.2024.06.006_bib41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.amjcard.2008.03.052","article-title":"Bivalirudin with provisional glycoprotein IIb\/IIIa inhibitors in patients undergoing primary angioplasty in the setting of cardiogenic shock","volume":"102","author":"Bonello","year":"2008","journal-title":"Am J Cardiol"},{"issue":"10","key":"10.1016\/j.iccl.2024.06.006_bib42","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1016\/j.cjca.2014.07.045","article-title":"Bivalirudin for primary percutaneous coronary interventions in patients with cardiogenic shock: Outcome assessment in the CAPITAL STEMI registry","volume":"30","author":"Pourdjabbar","year":"2014","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.iccl.2024.06.006_bib43","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in cardiogenic shock and after cardiopulmonary resuscitation: A global, multicenter, matched pair analysis with oral P2Y12 inhibition from the IABP-SHOCK II trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"issue":"7","key":"10.1016\/j.iccl.2024.06.006_bib44","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjacc\/zuad041","article-title":"Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and\/or with cardiogenic shock","volume":"12","author":"Zeymer","year":"2023","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"9","key":"10.1016\/j.iccl.2024.06.006_bib45","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s00392-021-01866-3","article-title":"Clopidogrel vs. prasugrel vs. ticagrelor in patients with acute myocardial infarction complicated by cardiogenic shock: A pooled IABP-SHOCK II and CULPRIT-SHOCK trial sub-analysis","volume":"110","author":"Orban","year":"2021","journal-title":"Clin Res Cardiol"},{"issue":"6","key":"10.1016\/j.iccl.2024.06.006_bib46","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.mayocp.2022.02.016","article-title":"Newer P2Y12 inhibitors vs clopidogrel in acute myocardial infarction with cardiac arrest or cardiogenic shock: A systematic review and meta-analysis","volume":"97","author":"Patlolla","year":"2022","journal-title":"Mayo Clin Proc"}],"container-title":["Interventional Cardiology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211745824000658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T18:55:39Z","timestamp":1725821739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211745824000658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S2211745824000658"],"URL":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.006","relation":{},"ISSN":["2211-7458"],"issn-type":[{"value":"2211-7458","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombotic Therapy in Patients with Complex Percutaneous Coronary Intervention and Cardiogenic Shock","name":"articletitle","label":"Article Title"},{"value":"Interventional Cardiology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iccl.2024.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}